PURPOSE: Mutations in the photoreceptor-specific protein peripherin/rds are associated with multiple retinal diseases. To date, attempts to achieve complete structural and functional rescue in animal models of peripherin/rds-induced retinal degeneration have not been successful. Gene therapy-directed approaches have been hindered by the haploinsufficiency phenotype, which dictates well-regulated expression of peripherin/rds protein levels. METHODS: Using a transgenic mouse line expressing wild-type peripherin/rds (NMP), the authors evaluated the critical in vivo level of peripherin/rds needed to maintain photoreceptor structure and ERG function and assessed the consequences of peripherin/rds overexpression in both rods and cones by Western blot and immunoprecipitation analyses, immunohistochemistry, electron microscopy, and electroretinography. The NMP transgene included a C-terminal modification (P341Q) to facilitate detection of the transgenic protein in the presence of wild-type peripherin/rds, using the monoclonal antibody 3B6. RESULTS: Peripherin/rds protein levels in NMP homozygotes were approximately 60% of wild-type levels. Western blot and immunoprecipitation analyses confirmed normal biochemical properties of the NMP protein when compared with wild-type peripherin/rds. Immunohistochemistry demonstrated appropriate localization of transgenic peripherin/rds protein to the disc rim region of photoreceptor outer segments. Total peripherin/rds levels in the retina were modulated by crossing NMP transgenic mice into different rds genetic backgrounds. A positive correlation was observed between peripherin/rds expression levels and the structural and functional integrity of photoreceptor outer segments. Overexpression of peripherin/rds caused no detectable adverse effects on rod or cone structure and function. CONCLUSIONS: These findings may have significant implications regarding therapeutic intervention in peripherin/rds-associated retinal diseases.
PURPOSE: Mutations in the photoreceptor-specific protein peripherin/rds are associated with multiple retinal diseases. To date, attempts to achieve complete structural and functional rescue in animal models of peripherin/rds-induced retinal degeneration have not been successful. Gene therapy-directed approaches have been hindered by the haploinsufficiency phenotype, which dictates well-regulated expression of peripherin/rds protein levels. METHODS: Using a transgenicmouse line expressing wild-type peripherin/rds (NMP), the authors evaluated the critical in vivo level of peripherin/rds needed to maintain photoreceptor structure and ERG function and assessed the consequences of peripherin/rds overexpression in both rods and cones by Western blot and immunoprecipitation analyses, immunohistochemistry, electron microscopy, and electroretinography. The NMP transgene included a C-terminal modification (P341Q) to facilitate detection of the transgenic protein in the presence of wild-type peripherin/rds, using the monoclonal antibody 3B6. RESULTS:Peripherin/rds protein levels in NMP homozygotes were approximately 60% of wild-type levels. Western blot and immunoprecipitation analyses confirmed normal biochemical properties of the NMP protein when compared with wild-type peripherin/rds. Immunohistochemistry demonstrated appropriate localization of transgenicperipherin/rds protein to the disc rim region of photoreceptor outer segments. Total peripherin/rds levels in the retina were modulated by crossing NMP transgenic mice into different rds genetic backgrounds. A positive correlation was observed between peripherin/rds expression levels and the structural and functional integrity of photoreceptor outer segments. Overexpression of peripherin/rds caused no detectable adverse effects on rod or cone structure and function. CONCLUSIONS: These findings may have significant implications regarding therapeutic intervention in peripherin/rds-associated retinal diseases.
Authors: E Tan; Q Wang; A B Quiambao; X Xu; N M Qtaishat; N S Peachey; J Lem; S J Fliesler; D R Pepperberg; M I Naash; M R Al-Ubaidi Journal: Invest Ophthalmol Vis Sci Date: 2001-03 Impact factor: 4.799
Authors: U Ekström; V Ponjavic; M Abrahamson; P Nilsson-Ehle; S Andrëasson; I Stenström; B Ehinger Journal: Ophthalmic Genet Date: 1998-03 Impact factor: 1.803
Authors: G Clarke; A F Goldberg; D Vidgen; L Collins; L Ploder; L Schwarz; L L Molday; J Rossant; A Szél; R S Molday; D G Birch; R R McInnes Journal: Nat Genet Date: 2000-05 Impact factor: 38.330
Authors: W Kedzierski; S Nusinowitz; D Birch; G Clarke; R R McInnes; D Bok; G H Travis Journal: Proc Natl Acad Sci U S A Date: 2001-06-26 Impact factor: 11.205
Authors: R R Ali; G M Sarra; C Stephens; M D Alwis; J W Bainbridge; P M Munro; S Fauser; M B Reichel; C Kinnon; D M Hunt; S S Bhattacharya; A J Thrasher Journal: Nat Genet Date: 2000-07 Impact factor: 38.330
Authors: Daniel Strayve; Mustafa S Makia; Mashal Kakakhel; Haarthi Sakthivel; Shannon M Conley; Muayyad R Al-Ubaidi; Muna I Naash Journal: Hum Mol Genet Date: 2020-09-29 Impact factor: 6.150
Authors: Shannon M Conley; Michael W Stuck; Justin L Burnett; Dibyendu Chakraborty; Seifollah Azadi; Steven J Fliesler; Muna I Naash Journal: Hum Mol Genet Date: 2014-01-25 Impact factor: 6.150